Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
Go back to Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors| (NASDAQ: PLRX) | Delayed: 1.12 +0.01 (0.90%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.11 | 52 Week High | $ | |||
| Open | $1.12 | 52 Week Low | $ | |||
| Day High | $1.13 | P/E | N/A | |||
| Day Low | $1.11 | EPS | $ | |||
| Volume | 105,812 | |||||
